Aphria (NASDAQ:APHA) released its quarterly earnings data on Wednesday. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.39), Briefing.com reports. The company had revenue of $160.50 million for the quarter, compared to analyst estimates of $153.75 million. Aphria had a negative net margin of 18.30% and a negative return on equity of 2.23%. The firm’s revenue for the quarter was up 33.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.03) earnings per share.
APHA stock opened at $12.42 on Friday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.30 and a current ratio of 5.37. The company has a 50 day moving average price of $7.62 and a 200 day moving average price of $6.45. Aphria has a fifty-two week low of $1.95 and a fifty-two week high of $14.01.
Several research analysts have recently commented on the company. CIBC boosted their target price on Aphria from $12.50 to $18.00 and gave the stock an “outperform” rating in a report on Friday. Canaccord Genuity raised Aphria from a “hold” rating to a “speculative buy” rating and boosted their target price for the stock from $11.00 to $17.50 in a report on Friday. Alliance Global Partners boosted their target price on Aphria from $12.00 to $20.00 and gave the stock a “buy” rating in a report on Friday. Cantor Fitzgerald boosted their target price on Aphria from $11.75 to $26.00 and gave the stock an “overweight” rating in a report on Friday. Finally, Stifel Nicolaus downgraded Aphria from a “buy” rating to a “hold” rating in a report on Thursday, December 17th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $14.23.
Aphria Inc cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands.
Recommended Story: Trading Ex-Dividend
Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.